BETHESDA, Md., Oct. 24, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that SPX-106T (the combination of D-tagatose and SPX-106) reduced dyslipidemia in new studies of apolipoprotein E-deficient mice and Syrian Golden hamsters. This finding corroborates data obtained in LDL receptor-deficient mice (see Spherix press release of September 8, 2011). Additionally, a new study in rats demonstrates that D-tagatose inhibits fructose absorption in the gastrointestinal tract, providing further insight into the mechanism of action of SPX-106T.
"Successful results in additional animal models increases our confidence going into human clinical trials with SPX-106T next spring," noted Dr. Claire Kruger, CEO of Spherix.
In a poster at the American Association of Pharmaceutical Scientists (AAPS) National Meeting, Spherix summarizes results obtained with SPX-106T in two strains of genetically engineered mice prone to dyslipidemia. SPX-106T significantly reduced VLDL and LDL cholesterol in LDL receptor-deficient mice fed normal chow. In apolipoprotein E-deficient mice fed a Western (high fat/high carbohydrate) diet, SPX-106T significantly reduced serum cholesterol by 30% (-307 mg/dl; p<0.05), prevented body weight gain (p<0.05), and significantly reduced the amount of subcutaneous, retroperitoneal, and epididymal fat (77, 90, 85% reductions, respectively, p<0.01) (see photo). SPX-106T did not affect the weight of other organs (heart, spleen, etc.). A recent range-finding dose study in hamsters fed the same Western diet and given SPX-106T provided evidence that the combination was effective in reducing serum triglycerides."An important new element in our work with SPX-106T is that we are now performing studies designed specifically to test therapy in diet-induced lipidemia, using dosing and timing information derived from the studies completed a few months ago in LDL receptor-deficient mice," said Dr. Robert Lodder, President of Spherix. The poster is authored by Dr. Kruger; Dr. Lodder; Dr. Dietrich Conze, Science Consultant; and Dr. A. Wallace Hayes, Principal Advisor. It will be presented at the AAPS National Meeting from 8 a.m. to 12 noon local time on Wednesday, October 26, 2011. The Meeting is being held at the Walter E. Washington Convention Center in Washington, D.C. from October 23 through 27. Spherix also demonstrates that D-tagatose blocks absorption of fructose through the gut. D-tagatose administered to Sprague-Daley rats in ascending doses was given in combination with 14C-fructose and blood levels of 14C-fructose were quantified over 60 minutes. Results showed that D-tagatose significantly decreased the amount of plasma 14C-fructose up to 30% (p<0.05). The resulting decrease in systemically absorbed fructose is a mechanism by which D-tagatose can effectively reduce diet-induced dyslipidemia.